1 3 J Endocrinol Invest
DOI 10.1007/s40618-016-0434-8
CONSENSUS STATEMENT
Italian association of clinical endocrinologists (AME) position
statement: drug therapy of osteoporosis
F. Vescini
1
· R. Attanasio
2
· A. Balestrieri
3
· F. Bandeira
4
· S. Bonadonna
5
·
V. Camozzi
6
· S. Cassibba
7
· R. Cesareo
8
· I. Chiodini
9
· C. Maria Francucci
10,11
·
L. Gianotti
12
· F. Grimaldi
1
· R. Guglielmi
13
· B. Madeo
14
· C. Marcocci
15
·
A. Palermo
16
· A. Scillitani
17
· E. Vignali
18
· V. Rochira
19
· M. Zini
20
Received: 28 September 2015 / Accepted: 22 January 2016
© The Author(s) 2016. This article is published with open access at Springerlink.com
the drugs available for this purpose. A short revision of the
literature about treatment of secondary osteoporosis due
both to androgen deprivation therapy for prostate cancer
and to aromatase inhibitors for breast cancer was also per-
formed. Also premenopausal females and males with osteo-
porosis are frequently seen in endocrine settings. Finally
particular attention was paid to the tailoring of treatment as
well as to its duration.
Abstract Treatment of osteoporosis is aimed to prevent
fragility fractures and to stabilize or increase bone mineral
density. Several drugs with different efficacy and safety
profiles are available. The long-term therapeutic strat-
egy should be planned, and the initial treatment should be
selected according to the individual site-specific fracture
risk and the need to give the maximal protection when the
fracture risk is highest (i.e. in the late life). The present
consensus focused on the strategies for the treatment of
postmenopausal osteoporosis taking into consideration all
Electronic supplementary material The online version of this
article (doi:10.1007/s40618-016-0434-8) contains supplementary
material, which is available to authorized users.
* R. Attanasio
roberto.serena@libero.it
F. Vescini
vescini.fabio@aoud.sanita.fvg.it
A. Balestrieri
【骨科】2016+AME立场声明：药物治疗骨质疏松症.pdf